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BACKGROUND
Progesterone is essential for the maintenance of pregnancy. However, whether 
progesterone supplementation in the first trimester of pregnancy would increase 
the rate of live births among women with a history of unexplained recurrent mis-
carriages is uncertain.
METHODS
We conducted a multicenter, double-blind, placebo-controlled, randomized trial to 
investigate whether treatment with progesterone would increase the rates of live 
births and newborn survival among women with unexplained recurrent miscar-
riage. We randomly assigned women with recurrent miscarriages to receive twice-
daily vaginal suppositories containing either 400 mg of micronized progesterone 
or matched placebo from a time soon after a positive urinary pregnancy test (and 
no later than 6 weeks of gestation) through 12 weeks of gestation. The primary 
outcome was live birth after 24 weeks of gestation.
RESULTS
A total of 1568 women were assessed for eligibility, and 836 of these women who 
conceived naturally within 1 year and remained willing to participate in the trial 
were randomly assigned to receive either progesterone (404 women) or placebo 
(432 women). The follow-up rate for the primary outcome was 98.8% (826 of 836 
women). In an intention-to-treat analysis, the rate of live births was 65.8% (262 of 
398 women) in the progesterone group and 63.3% (271 of 428 women) in the 
placebo group (relative rate, 1.04; 95% confidence interval [CI], 0.94 to 1.15; rate 
difference, 2.5 percentage points; 95% CI, −4.0 to 9.0). There were no significant 
between-group differences in the rate of adverse events.
CONCLUSIONS
Progesterone therapy in the first trimester of pregnancy did not result in a sig-
nificantly higher rate of live births among women with a history of unexplained 
recurrent miscarriages. (Funded by the United Kingdom National Institute of 
Health Research; PROMISE Current Controlled Trials number, ISRCTN92644181.)
A BS TR AC T
A Randomized Trial of Progesterone  
in Women with Recurrent Miscarriages
A. Coomarasamy, H. Williams, E. Truchanowicz, P.T. Seed, R. Small, S. Quenby, 
P. Gupta, F. Dawood, Y.E.M. Koot, R. Bender Atik, K.W.M. Bloemenkamp, 
R. Brady, A.L. Briley, R. Cavallaro, Y.C. Cheong, J.J. Chu, A. Eapen, A. Ewies, 
A. Hoek, E.M. Kaaijk, C.A.M. Koks, T.-C. Li, M. MacLean, B.W. Mol, J. Moore, 
J.A. Ross, L. Sharpe, J. Stewart, N. Vaithilingam, R.G. Farquharson, M.D. Kilby, 
Y. Khalaf, M. Goddijn, L. Regan, and R. Rai 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF BIRMINGHAM on November 26, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;22 nejm.org November 26, 20152142
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Recurrent miscarriage, defined as the loss of three or more pregnancies, affects approximately 1% of couples who 
attempt to have a child.1 Even after comprehen-
sive investigations, a cause for recurrent miscar-
riage is identified in less than half of these 
couples.1,2 Unexplained recurrent miscarriage is 
associated with substantial adverse clinical and 
psychological consequences for the women and 
their families. Various therapeutic strategies to 
increase the rate of live births among these 
women have been evaluated, but no effective 
treatment has been identified.
Progesterone is essential to achieve and main-
tain a healthy pregnancy. It is secreted naturally 
by the corpus luteum during the second half of 
the menstrual cycle and by the corpus luteum 
and placenta during early pregnancy. Progesterone 
prepares the endometrium for implantation of 
the embryo. If implantation occurs, the corpus 
luteum continues to produce progesterone, but 
between 8 and 12 weeks of gestation, the pla-
centa takes over this role and maintains the 
pregnancy thereafter.3
The physiological importance of progesterone 
in early pregnancy has prompted the performance 
of several trials to evaluate the effect of proges-
terone supplementation in the first trimester of 
pregnancy among women with a history of re-
current miscarriages. A Cochrane review of four 
small trials showed a significantly lower risk of 
miscarriages among women who received pro-
gesterone than among those who received pla-
cebo or no treatment (odds ratio, 0.39; 95% 
confidence interval [CI], 0.21 to 0.72), but the 
quality of the four trials was considered to be 
poor.4 We designed this multicenter, randomized, 
placebo-controlled trial (Progesterone in Recur-
rent Miscarriages [PROMISE]) to investigate 
whether treatment with progesterone would in-
crease the rates of live births and newborn sur-
vival among women with unexplained recurrent 
miscarriage.
Me thods
Study Oversight
The PROMISE trial was approved by the United 
Kingdom Medicines and Healthcare Products 
Regulatory Authority, the National Research 
Ethics Service, and the research and develop-
ment department at each participating hospital. 
Progesterone and placebo were manufactured 
and supplied by Besins Healthcare. This com-
pany had no role in the design of the study; the 
collection, analysis, or interpretation of the data; 
or the writing of the report. All the authors were 
involved in the collection, analysis, and interpre-
tation of the data; the writing and critical review 
of the manuscript; and the decision to submit 
the manuscript for publication. Study oversight 
and monitoring were provided by a trial steering 
committee and by an independent data and safety 
monitoring committee. The first, second, and 
last authors vouch for the accuracy of the data 
and analyses and for the fidelity of the study to 
the protocol (available with the full text of this 
article at NEJM.org).
Study Participants
The participants in the PROMISE trial were re-
cruited from hospitals located across the United 
Kingdom (36 sites) and in the Netherlands (9 sites). 
Women were eligible for enrollment in the study 
if they were 18 to 39 years of age and were ac-
tively trying to conceive naturally after having 
received a diagnosis of unexplained recurrent 
miscarriage (defined as three or more consecu-
tive or nonconsecutive losses of pregnancy in the 
first trimester). Age criteria were applied for 
participation in the trial because the likelihood 
of miscarriages due to random chromosomal 
aberrations increases with advancing age,1,5 and 
progesterone therapy would probably not prevent 
such miscarriages.
All participants gave written informed con-
sent. Participants were excluded from random-
ization if they were unable to conceive naturally 
within 1 year after recruitment; had the anti-
phospholipid syndrome or other recognized 
thrombophilic conditions; had uterine cavity 
abnormalities (as assessed with the use of ultra-
sonography, hysterosonography, hysterosalpin-
gogram, or hysteroscopy), an abnormal parental 
karyotype, or other identifiable cause of recur-
rent miscarriage such as diabetes, thyroid dis-
ease, or systemic lupus erythematosus (tests 
were initiated only if clinically indicated); were 
currently receiving heparin therapy; or had con-
traindications to progesterone use.
Study Design and Drug Regimen
Participants were randomly assigned in a 1:1 ratio 
to receive vaginal suppositories containing either 
400 mg of micronized progesterone (Utrogestan, 
Besins Healthcare) twice daily or matched pla-
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cebo from a time soon after receiving positive 
results on a urinary pregnancy test (and no later 
than 6 weeks of gestation) through 12 completed 
weeks of gestation (or earlier if an ectopic preg-
nancy was diagnosed or miscarriage occurred 
before 12 weeks). Computerized randomization 
was performed centrally through a secure Inter-
net facility with the use of minimization to bal-
ance the study-group assignments according to 
the number of previous miscarriages (3 or ≥4), 
maternal age (≤35 or >35 years), presence or 
absence of polycystic ovaries, and body-mass 
index (BMI [the weight in kilograms divided by 
the square of the height in meters], ≤30 or >30). 
The appearance, route, and timing of adminis-
tration of the study drugs were identical in the 
placebo and progesterone groups. Participants, 
physicians, and trial nurses were unaware of the 
study-group assignments throughout the trial.
Outcome Measures
The primary outcome measure was live birth after 
24 completed weeks of gestation. Secondary out-
comes included clinical pregnancy (presence of at 
least a gestational sac) at 6 to 8 weeks, ongoing 
pregnancy with fetal heart activity at 12 weeks, 
miscarriage (pregnancy loss before 24 weeks of 
gestation), the week of gestation at delivery, sur-
vival at 28 days of neonatal life, and congenital 
abnormalities (specifically genital anomalies, be-
cause there has been concern about a possible 
increased risk of hypospadias with the use of 
certain progesterone analogues6). Exploratory 
outcomes included obstetrical conditions such 
as preeclampsia, small size for gestational age 
(<10th percentile for birth weight), preterm pre-
labor rupture of membranes, antepartum hemor-
rhage, and mode of delivery, as well as neonatal 
variables such as birth weight, arterial and ve-
nous pH, Apgar scores, and need for ventilation 
support.
Statistical Analysis
We calculated that we would need to assign 376 
women to each study group for the study to have 
80% power to detect a minimally important ab-
solute difference of 10 percentage points be-
tween the progesterone group and the placebo 
group with respect to the rate of live births after 
24 weeks (from 60% to 70%; odds ratio, 1.56), at 
an alpha level of 0.05. We planned to include 790 
women in the study to account for a 5% rate of 
loss to follow-up.
Categorical baseline data were reported as ab-
solute numbers and percentages. Normally dis-
tributed continuous variables were summarized 
as means with standard deviations, and nonnor-
mally distributed continuous variables were re-
ported as medians with interquartile ranges. The 
analyses were performed according to the inten-
tion-to-treat principle. Binary regression with a 
log-link function was used to determine the 
relative rates for the primary outcome and other 
binary outcomes, with adjustment for the mini-
mization variables. Continuous outcomes were 
analyzed as mean differences or ratios, as appro-
priate.
The primary end point was analyzed with the 
use of multivariate logistic regression in three 
prespecified subgroups defined according to 
maternal age (≤35 vs. >35 years), number of pre-
vious miscarriages (3 vs. ≥4), and presence or 
absence of polycystic ovaries, and in three addi-
tional post hoc subgroups defined according to 
gestation at treatment start (<5 weeks 0 days vs. 
≥5 weeks 0 days), BMI (≤30 vs. >30), and country 
(United Kingdom vs. the Netherlands). In each 
subgroup analysis, we first used a chi-square 
test for interaction to determine whether the ef-
fects of progesterone and placebo differed in any 
of the subgroups.
Interim analyses of principal safety and ef-
fectiveness end points were performed on behalf 
of the data and safety monitoring committee on 
two occasions. Because these analyses were per-
formed with the use of the Peto principle,7 no 
adjustment was made in the final P values to 
determine significance.
R esult s
Study Participants
A total of 1568 women were assessed for eligi-
bility for the PROMISE trial from June 23, 2010, 
through October 23, 2013, and 836 of these 
women who conceived naturally within 1 year and 
remained willing to participate in the trial were 
randomly assigned to receive either progesterone 
(404 women) or placebo (432 women) (Fig. 1). The 
follow-up rate for the primary outcome was 98.8% 
(826 of 836 women). The baseline characteristics 
were similar in the two study groups (Table 1).
Outcomes
The rate of live births after 24 weeks of gestation 
was 65.8% (262 of 398 pregnancies) in the pro-
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gesterone group, as compared with 63.3% (271 of 
428 pregnancies) in the placebo group (relative 
rate, 1.04; 95% CI, 0.94 to 1.15; absolute rate dif-
ference, 2.5 percentage points; 95% CI, −4.0 to 9.0).
There were no significant between-group dif-
ferences in the rates of clinical pregnancy (at 6 
to 8 weeks), ongoing pregnancy (at 12 weeks), 
ectopic pregnancy, miscarriage, stillbirth, and 
neonatal outcomes, as well as in the median 
gestational age at miscarriage (Table 2). A total 
of 533 pregnancies in the two study groups pro-
gressed to live birth after 24 weeks; the babies 
were delivered before 34 weeks in 10 of 262 
pregnancies (3.8%) in the progesterone group 
Figure 1. Enrollment, Randomization, Follow-up, and Analysis.
836 Underwent randomization
1568 Patients were assessed for eligibility
732 Were excluded
202 Declined to participate or withdrew
515 Were not pregnant within 1 yr
10 Had fetuses with a gestational age
>42 days or uncertain date of last 
menstrual period
4 Were not eligible when reassessed
2 Were receiving heparin
1 Had thrombolytic disorder
1 Was >39 yr of age
1 Had unknown reason
404 Were assigned to receive progesterone 432 Were assigned to receive placebo
6 Were lost to follow-up 4 Were lost to follow-up
428 Were included in the analysis
433 Fetuses were included in the analysis
271 Deliveries with information (excluding
early pregnancy losses) were included
in the analysis
398 Were included in the analysis
402 Fetuses were included in the analysis
262 Deliveries with information (excluding
early pregnancy losses) were included
in the analysis
8 Discontinued intervention
1 Had adverse events
4 Were prescribed progesterone
independently of the study
3 Withdrew consent
9 Discontinued intervention
3 Had adverse events
2 Were prescribed progesterone
independently of the study
4 Withdrew consent
387 Received assigned intervention
17 Did not receive assigned intervention
10 Had pregnancy end before start
of intervention
4 Withdrew consent before start
of intervention
3 Received progesterone before
start of intervention
423 Received assigned intervention
9 Did not receive assigned intervention
7 Had pregnancy end before start
of intervention
1 Withdrew consent before start
of intervention
1 Received progesterone before
start of intervention
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and in 10 of 271 pregnancies (3.7%) in the pla-
cebo group (relative risk, 1.03; 95% CI, 0.44 to 
2.45). The distributions of gestational age at the 
time of live-birth delivery were similar in the 
two study groups (Fig. 2).
The frequency of adverse events did not differ 
Characteristic
Progesterone 
(N = 404)
Placebo 
(N = 432)
Maternal age — yr†
Median 32.9 32.5
Interquartile range 29.3–36.3 28.9–35.9
Maternal BMI 25.5±5.1 25.3±5.1
Maternal BMI >30.0 — no./total no. (%) 63/404 (15.6) 65/432 (15.0)
Maternal race — no./total no. (%)‡
White 316/399 (79.2) 366/424 (86.3)
Black 16/399 (4.0) 19/424 (4.5)
Asian 39/399 (9.8) 29/424 (6.8)
Other, including mixed race 28/399 (7.0) 10/424 (2.4)
Maternal smoking — no./total no. (%)
Nonsmoker 339/404 (83.9) 363/432 (84.0)
<10 cigarettes/day 28/404 (6.9) 34/432 (7.9)
10 to 19 cigarettes/day 31/404 (7.7) 27/432 (6.2)
≥20 cigarettes/day 6/404 (1.5) 8/432 (1.9)
Alcohol use — no./total no. (%)§
None 229/404 (56.7) 260/432 (60.2)
≤3 units/day 92/404 (22.8) 89/432 (20.6)
>3 to ≤20 units/day 82/404 (20.3) 83/432 (19.2)
>20 units/day 1/404 (0.2) 0/432
Parity
Previous live birth — no./total no. (%) 167/404 (41.3) 179/432 (41.4)
≥4 previous miscarriages — no./total no. (%) 183/404 (45.3) 192/432 (44.4)
Previous pregnancy losses — no.
Median 3.0 3.0
Interquartile range 3.0–5.0 3.0–4.0
Clinical risk factors — no./total no. (%)
Polycystic ovaries 30/404 (7.4) 28/432 (6.5)
Fibroids 15/404 (3.7) 14/432 (3.2)
Large-loop excision of the cervical transformation zone 10/404 (2.5) 19/432 (4.4)
Family history of recurrent miscarriages 55/368 (14.9) 63/391 (16.1)
Concurrent medications — no./total no. (%)
Metformin 4/404 (1.0) 2/432 (0.5)
Aspirin 38/404 (9.4) 37/432 (8.6)
*  Plus–minus values are means ±SD. The baseline data (age, body-mass index [BMI; the weight in kilograms divided by 
the square of the height in meters], maternal race, smoking status, and parity) of the participants were similar (without 
significant differences) in the two study groups.
†  Listed is the maternal age at the time of randomization.
‡  Race was self-reported.
§  One unit is 10 g of pure alcohol.
Table 1. Characteristics of the Participants at Baseline.*
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significantly between the progesterone group 
and the placebo group (Table S1 in the Supple-
mentary Appendix, available at NEJM.org). Neo-
natal congenital anomalies were observed in 
3.5% of the babies (8 of 266 babies [3.0%] in the 
progesterone group, as compared with 11 of 276 
babies [4.0%] in the placebo group; relative risk, 
0.75; 95% CI, 0.31 to 1.85). A urogenital abnor-
mality was observed in 1 baby in each group 
(a hypospadias in the progesterone group and 
a urachal cyst in the placebo group).
No evidence of effect modification was iden-
tified in the prespecified subgroups (defined 
according to maternal age, number of previous 
miscarriages, and presence or absence of poly-
cystic ovaries) or in the post hoc subgroups 
(defined according to gestation at the start of 
treatment, BMI, and country) (Table S2 in the 
Supplementary Appendix). In exploratory analy-
ses, we found no significant differences between 
the two study groups in the rates of obstetrical 
or neonatal adverse outcomes (Table S3 in the 
Supplementary Appendix).
Discussion
This large multicenter, randomized, placebo-
controlled trial showed that progesterone ther-
apy in the first trimester of pregnancy did not 
result in a significant increase in the rate of live 
births among women with a history of unex-
plained recurrent miscarriages. Our results do 
not support earlier findings of a Cochrane 
analysis that suggested a benefit of progesterone 
therapy in the first trimester of pregnancy.4 The 
Cochrane analysis pooled the results from four 
small trials that had substantive methodologic 
limitations8-11; none of the trials specified the 
method of concealment of study-group assign-
ments, and only two trials used a placebo for 
comparison. A more recent double-blind, placebo-
controlled, randomized trial of oral dydroges-
terone (given from the time that pregnancy was 
confirmed until 20 weeks of gestation) among 
360 women with a history of recurrent miscar-
riages also showed a benefit of progesterone in 
reducing a subsequent risk of miscarriage12 
Outcome Progesterone Placebo Relative Risk (95% CI) P Value
no./total no. (%)
Pregnancy outcomes
Clinical pregnancy at 6 to 8 weeks 326/398 (81.9) 334/428 (78.0) 1.05 (0.98–1.12) 0.16
Ongoing pregnancy at 12 weeks 267/398 (67.1) 277/428 (64.7) 1.04 (0.94–1.14) 0.47
Ectopic pregnancy 6/398 (1.5) 7/428 (1.6) 0.92 (0.31–2.72) 0.88
Miscarriage* 128/398 (32.2) 143/428 (33.4) 0.96 (0.79–1.17) 0.70
Stillbirth 1/398 (0.3) 2/428 (0.5) 0.54 (0.05–5.92) 0.61
Live birth after 24 weeks 0 days of gestation† 262/398 (65.8) 271/428 (63.3) 1.04 (0.94–1.15) 0.45
Twin live births after 24 weeks 0 days of 
 gestation†
4/398 (1.0) 5/428 (1.2) 0.86 (0.23–3.18) 0.82
Gestation outcomes among women with live births
Live birth before 28 weeks 0 days of gestation 1/262 (0.4) 1/271 (0.4) 1.03 (0.06–16.49) 0.98
Live birth before 34 weeks 0 days of gestation 10/262 (3.8) 10/271 (3.7) 1.03 (0.44–2.45) 0.94
Live birth before 37 weeks 0 days of gestation 27/262 (10.3) 25/271 (9.2) 1.12 (0.67–1.87) 0.68
Neonatal outcomes‡
Any congenital anomaly 8/266 (3.0) 11/276 (4.0) 0.75 (0.31–1.85) 0.54
Genital congenital anomaly 1/266 (0.4) 1/276 (0.4) 1.04 (0.07–16.50) 0.98
Newborn survival to 28 days† 260/261 (99.6) 269/269 (100) 1.00 (0.99–1.00) 0.32
*  The median gestational age at miscarriage was 7.3 weeks (interquartile range, 6.0 to 8.7) in the progesterone group and 7.1 weeks (inter-
quartile range, 6.0 to 8.5) in the placebo group (relative risk, 0.0; 95% CI, −0.6 to 0.4; P = 0.87).
†  The end point is listed per trial participant.
‡  The end point is listed per neonate.
Table 2. Primary Outcome and Secondary Outcomes.
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(relative risk of miscarriage with placebo, as 
compared with dydrogesterone, 2.4; 95% CI, 1.3 
to 5.9); there were no significant between-group 
differences in the rates of preterm birth, cesar-
ean deliveries, or babies with low birth weights. 
None of the previous trials assessed rates of live 
births.
Several limitations of our study should be 
considered. We studied a vaginal preparation of 
progesterone, at a dose of 400 mg twice daily, 
and it is possible that the results with this regi-
men are not generalizable to patients receiving 
other doses and preparations. However, we chose 
this route to deliver a greater proportion of the 
drug to the biologically relevant site (i.e., the 
uterus),13,14 and the dose used (400 mg twice daily) 
represents a dose at the top end of the therapeu-
tic window.15 Some researchers have suggested 
that intramuscular preparations of progesterone 
may provide greater therapeutic benefit than 
vaginal preparations; however, data are lacking 
to support this contention, and previous trials of 
alternative progesterone preparations (including 
intramuscular progesterone) have shown varying 
results.8,9 Furthermore, previous studies have 
shown the efficacy of vaginal progesterone in 
lowering the risk of preterm birth.16-18
We initiated progesterone treatment after 
pregnancy was confirmed, and thus our study 
cannot address whether progesterone supple-
mentation could be more effective in reducing 
the risk of miscarriage if administered during 
the luteal phase of the cycle, before the confir-
mation of pregnancy.19-22 We discontinued pro-
gesterone at 12 weeks of gestation but consider 
it unlikely that therapy beyond this time would 
result in better outcomes; it is well documented 
that corpus luteal function is replaced by placen-
tal production of progesterone before the end of 
the first trimester.3 Moreover, among PROMISE 
participants who had a miscarriage, the median 
gestation was less than 8 weeks (7.3 weeks in 
the progesterone group and 7.1 weeks in the 
placebo group).
We found no increase in the risk of congeni-
tal anomalies among offspring of women treated 
with progesterone, although the study was not 
powered for such rare outcomes. Nonetheless, 
this finding is reassuring because progesterone 
therapy is commonly used as part of assisted-
conception treatment.
In conclusion, our trial showed no significant 
increase in the rate of live births with the use 
of vaginal progesterone in the first trimester of 
pregnancy among women with recurrent miscar-
riages. Our results do not support the earlier 
findings of a Cochrane review4 that suggested a 
benefit of progesterone therapy in the first trimes-
ter among women with recurrent miscarriages.
This report presents independent research commissioned by 
the National Institute for Health Research (NIHR). A mono-
graph reporting the data collected in this study will be pub-
lished in the NIHR Journals Library. Further information is 
available at www . journalslibrary . nihr . ac . uk/ hta. The views and 
opinions expressed by authors in this publication are those of 
the authors and do not necessarily reflect those of the NHS, the 
NIHR, the Medical Research Council, the Central Commission-
ing Facility, the NIHR Evaluation, Trials and Studies Coordinat-
ing Center, the Health Technology Assessment program, or the 
Department of Health.
Supported by the United Kingdom NIHR Health Technology 
Assessment program (project number HTA 08 38 01).
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank all the women who participated in this study; the 
following investigators for supervising recruitment and randomi-
zation at the study centers: Dr. Shamma Al-Inizi, Dr. Adjoa Appiah, 
Dr. Maysoon Backos, Mr. Faisal Basama, Mr. Steve Bober, Dr. 
Manisha Chandra, Dr. Sangeeta Das, Dr. Edmond Edi-Osagie, 
Dr. Isaac Evbuomwan, Dr. Joanna Fuller, Dr. Elizabeth Haslett, 
Dr. Shehnaz Jivraj, Dr. Lisa Joels, Dr. Anjali Kalaskar, Mr. Jaya-
prakasan Kanna, Dr. Walter Kuchenbecker, Dr. Shonag Macken-
zie, Dr. Iona MacLeod, Dr. Padma Manda, Dr. Patricia Mercelina, 
Dr. Neela Mukhopadhaya, Dr. Nalini Munjuluri, Dr. Denise Per-
quin, Dr. Judith Roberts, Mr. Gamal Sayed, Ms. Gillian Scothern, 
Dr. Seema Sen, Mr. Guy Thorpe-Beeston, Dr. Sandra Watson, and 
Mr. Simon Wood; all the PROMISE research nurses who assisted 
in the collection of data; Dr. Christine Godfrey and Dr. Peter 
Braude for providing advice and assistance in the design of the 
study; Dr. Siladitya Bhattacharya for chairing the trial steering 
committee; Dr. Jennifer Kurinczuk for chairing the data and safe-
Figure 2. Distribution of Gestational Age According to Study Group Assignment.
Only pregnancies that continued beyond 24 weeks are shown. The hazard 
ratio for miscarriage in the progesterone group, as compared with the pla-
cebo group, was 1.04 (95% CI, 0.91 to 1.19).
D
el
iv
er
ie
s 
(%
)
100
75
50
25
0
0 25 30 35 40 45
Gestation (wk)
Progesterone
Placebo
 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF BIRMINGHAM on November 26, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;22 nejm.org November 26, 20152148
Progesterone in Women with Recurrent Miscarriages
ty monitoring committee; Dr. Javier Zamora and Dr. Nick Raine-
Fenning for participating in the data monitoring committee; 
study pharmacists Ms. Victoria Latham and Ms. Sonjya El Yan-
douzi; service user representative Ms. Liz Campbell; officers of 
the Royal College of Obstetricians and Gynecologists Women’s 
Network (formerly known as the Royal College of Obstetricians 
and Gynecologists Consumers’ Forum); and all those not otherwise 
mentioned above who have contributed to the PROMISE study.
Appendix
The authors’ full names and academic degrees are as follows: Arri Coomarasamy, M.B., Ch.B., M.D., Helen Williams, B.Sc., Ewa 
Truchanowicz, Ph.D., Paul T. Seed, M.Sc., Rachel Small, R.G.N., R.M., Siobhan Quenby, M.D., Pratima Gupta, M.D., Feroza Dawood, 
M.B., Ch.B., M.D., Yvonne E.M. Koot, M.D., Ruth Bender Atik, B.A., Kitty W.M. Bloemenkamp, M.D., Ph.D., Rebecca Brady, R.N.Dip., 
M.Sc., T.N.Dip., Annette L. Briley, Ph.D., Rebecca Cavallaro, R.M., R.N., M.Mid., Ying C. Cheong, M.B., Ch.B., M.D., Justin J. Chu, 
M.D., Abey Eapen, M.D., Ayman Ewies, M.B., Ch.B., M.D., Annemieke Hoek, M.D., Ph.D., Eugenie M. Kaaijk, M.D., Carolien A.M. 
Koks, M.D., Tin-Chiu Li, M.D., Marjory MacLean, M.D., Ben W. Mol, M.D., Ph.D., Judith Moore, M.R.C.O.G., Jackie A. Ross, M.B., 
B.S., Lisa Sharpe, R.M.Dip., Jane Stewart, M.B., Ch.B., M.D., Nirmala Vaithilingam, M.D., Roy G. Farquharson, M.D., Mark D. Kilby, 
M.B., B.S., M.D., Yacoub Khalaf, M.B., B.Ch., M.D., Mariette Goddijn, M.D., Ph.D., Lesley Regan, M.D., and Rajendra Rai, M.D.
The authors’ affiliations are as follows: the College of Medical and Dental Sciences, University of Birmingham (A.C., H.W., E.T., 
J.J.C., A. Eapen, M.D.K.), Heart of England NHS Foundation Trust (R.S., P.G.), and Sandwell and West Birmingham Hospitals NHS 
Teaching Trust (A. Ewies), Birmingham, King’s College London and King’s Health Partners at St. Thomas’ Hospital (P.T.S.), Women’s 
Health Research Center, Imperial College at St. Mary’s Hospital Campus (R.B., R.C., L.S., L.R., R.R.), King’s Health Partners at St. 
Thomas’ Hospital (A.L.B.), King’s College Hospital NHS Foundation Trust (J.A.R.), and Assisted Conception Unit, Guy’s and St. 
Thomas’ Foundation Trust (Y.K.), London, Biomedical Research Unit in Reproductive Health, University of Warwick, Warwick (S.Q.), 
Liverpool Women’s NHS Foundation Trust (F.D., R.G.F.), Liverpool, The Miscarriage Association, Wakefield (R.B.A.), University of 
Southampton Faculty of Medicine, Princess Anne Hospital, Southampton (Y.C.C.), Royal Hallamshire Hospital, Sheffield (T.-C.L.), 
Ayrshire Maternity Unit, University Hospital of Crosshouse, Kilmarnock (M.M.), Nottingham University Hospitals NHS Trust, Nottingham 
(J.M.), Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne (J.S.), and Portsmouth Hospitals NHS Trust, Portsmouth (N.V.) 
— all in the United Kingdom; the Department of Reproductive Medicine, University Medical Center Utrecht, Utrecht (Y.E.M.K.), the 
Department of Obstetrics, Leiden University Medical Center, Leiden (K.W.M.B.), the Department of Reproductive Medicine and Gynecol-
ogy, University of Groningen, Groningen (A.H.), the Department of Obstetrics and Gynecology, Onze Lieve Vrouwe Gasthuis (E.M.K.), and 
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Academic Medical Center (M.G.), Amsterdam, and the De-
partment of Obstetrics and Gynecology, Maxima Medical Center Veldhoven, Veldhoven (C.A.M.K.) — all in the Netherlands; and the 
Robinson Institute, School of Pediatrics and Reproductive Health, University of Adelaide, Adelaide, SA, Australia (B.W.M.).
References
1. Rai R, Regan L. Recurrent miscar-
riage. Lancet 2006; 368: 601-11.
2. Practice Committee of the American 
Society for Reproductive Medicine. Evalu-
ation and treatment of recurrent preg-
nancy loss: a committee opinion. Fertil 
Steril 2012; 98: 1103-11.
3. Malassiné A, Frendo JL, Evain-Brion D. 
A comparison of placental development 
and endocrine functions between the 
human and mouse model. Hum Reprod 
Update 2003; 9: 531-9.
4. Haas DM, Ramsey PS. Progestogen 
for preventing miscarriage. Cochrane 
Database Syst Rev 2013; 10: CD003511.
5. Stephenson MD, Awartani KA, Robin-
son WP. Cytogenetic analysis of miscar-
riages from couples with recurrent mis-
carriage: a case-control study. Hum 
Reprod 2002; 17: 446-51.
6. Carmichael SL, Shaw GM, Laurent C, 
Croughan MS, Olney RS, Lammer EJ. 
Maternal progestin intake and risk of 
 hypospadias. Arch Pediatr Adolesc Med 
2005; 159: 957-62.
7. Peto R, Pike MC, Armitage P, et al. 
Design and analysis of randomized clini-
cal trials requiring prolonged observation 
of each patient. I: introduction and de-
sign. Br J Cancer 1976; 34: 585-612.
8. Swyer GI, Daley D. Progesterone im-
plantation in habitual abortion. Br Med J 
1953; 1: 1073-7.
9. Levine L. Habitual abortion: a con-
trolled study of progestational therapy. 
West J Surg Obs Gynecol 1964; 72: 30-6.
10. Goldzieher JW. Double-blind trial of 
a progestin in habitual abortion. JAMA 
1964; 188: 651-4.
11. El-Zibdeh MY. Dydrogesterone in the re-
duction of recurrent spontaneous abortion. 
J Steroid Biochem Mol Biol 2005; 97: 431-4.
12. Kumar A, Begum N, Prasad S, Aggar-
wal S, Sharma S. Oral dydrogesterone 
treatment during early pregnancy to pre-
vent recurrent pregnancy loss and its role 
in modulation of cytokine production: 
a double-blind, randomized, parallel, pla-
cebo-controlled trial. Fertil Steril 2014; 
102(5): 1357.e3-1363.e3.
13. Bulletti C, de Ziegler D, Flamigni C, 
et al. Targeted drug delivery in gynaecol-
ogy: the first uterine pass effect. Hum 
Reprod 1997; 12: 1073-9.
14. Cicinelli E, Cignarelli M, Sabatelli S, 
et al. Plasma concentrations of progester-
one are higher in the uterine artery than 
in the radial artery after vaginal adminis-
tration of micronized progesterone in an 
oil-based solution to postmenopausal 
women. Fertil Steril 1998; 69: 471-3.
15. Nosarka S, Kruger T, Siebert I, Grove D. 
Luteal phase support in in vitro fertiliza-
tion: meta-analysis of randomized trials. 
Gynecol Obs Invest 2005; 60: 67-74.
16. Coomarasamy A, Truchanowicz EG, 
Rai R. Does first trimester progesterone 
prophylaxis increase the live birth rate in 
women with unexplained recurrent mis-
carriages? BMJ 2011; 342: d1914.
17. Da Fonseca EB, Bittar RE, Carvalho 
MH, Zugaib M. Prophylactic administra-
tion of progesterone by vaginal supposi-
tory to reduce the incidence of spontane-
ous preterm birth in women at increased 
risk: a randomized placebo-controlled 
double-blind study. Am J Obstet Gynecol 
2003; 188: 419-24.
18. Fonseca EB, Celik E, Parra M, Singh 
M, Nicolaides KH. Progesterone and the 
risk of preterm birth among women with a 
short cervix. N Engl J Med 2007; 357: 462-9.
19. Daya S. Efficacy of progesterone sup-
port for pregnancy in women with recur-
rent miscarriage: a meta-analysis of con-
trolled trials. Br J Obstet Gynaecol 1989; 
96: 275-80.
20. Ozlü T, Güngör AC, Dönmez ME, Du-
ran B. Use of progestogens in pregnant 
and infertile patients. Arch Gynecol Obstet 
2012; 286: 495-503.
21. Sonntag B, Ludwig M. An integrated 
view on the luteal phase: diagnosis and 
treatment in subfertility. Clin Endocrinol 
(Oxf) 2012; 77: 500-7.
22. Shah D, Nagarajan N. Luteal insuffi-
ciency in first trimester. Indian J Endocri-
nol Metab 2013; 17: 44-9.
Copyright © 2015 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF BIRMINGHAM on November 26, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
